Informa Australia is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Choose Location

Register Your Interest


Current FDA perspectives on accelerating Cell & Gene Therapies development

Date: Wednesday, 25th October 2023
8:00am IST (India)/ 10:30am CST(Shanghai) / 11:30am JST(Tokyo) / 13:30pm AEDT(Sydney)
Where: Online Webinar



The field of Cell and Gene Therapies (CAGTs) holds tremendous promise for providing transformative benefits for unmet clinical needs. However, biological complexity poses many challenges throughout the lifecycle of CAGT product development. Keeping up-to-date with key trends and the latest Health Authority (HA) updates, as well as understanding the phase-specific HA requirements, provides a roadmap for planning a CAGT development program. This knowledge can help you bring these complex treatments to market faster and more efficiently.

This webinar will discuss:

  • Overview of Key Trends in the Cell and Gene Therapy Space
  • FDA Regulatory Updates
  • Restructuring of the Cell & Gene Therapy Office at FDA (formerly OTAT/CBER, now known as OTP)
  • PDUFA VII initiatives
  • Recent high-profile public comments by CBER/FDA Upper Level Management on Accelerated Approval relevant for CAGT sponsors
  • Maximizing Interactions with OTP: Focus on INTERACT Early Engagement Meeting
  • Expedited Development Programs: Focus on RMAT (Regenerative Medicine Advanced Therapy) for CAGT
  • Operationalizing Delivery to Patients for Investigational Trialing
  • Importance of Manufacturing Quality Products for Patients – Investigational and Commercial
  • Lessons Learned for CGT clinical development
  • Important take home messages from recent FDA approvals of CAGT products


Click here to register for this free webinar


Chris Learn

PhD, PMP, Vice President, Cell and Gene Therapy Center of Excellence, Parexel International

Steve Winitsky

MD, Vice President, Technical, Regulatory & Access, Parexel International

Speaker Bios


Chris Learn

PhD, PMP, Vice President, Cell and Gene Therapy Center of Excellence, Parexel International

Chris has 20 years of clinical trial execution and team management experience, a subject matter experts overseeing the clinical development programs of >20 cell and gene therapy programs in rare disease, CNS, pediatrics, and oncology for emerging biotech portfolios and large-cap pharma. His current interests and commitments lie in the phasing of dose, route, and administration of cell and gene therapies in the clinic and how to use innovations in immunotherapy to drive these unique therapies further in improving patient outcomes.



Steve Winitsky

MD, Vice President, Technical, Regulatory & Access, Parexel International

Steve spent more than 11 years at the FDA as a former Medical Officer, Team Leader, and Acting Branch Chief in the Center for Biologics Evaluation and Research’s (CBER’s) Office of Tissues and Advanced Therapies, which has recently been renamed the Office of Therapeutic Products (OTP). He has extensive experience with the review and supervision of cell and gene therapy (CGT) applications, including sponsor requests for Breakthrough Therapy and Regenerative Medicine Advanced Therapy designation. He also supervised numerous Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) and pre-IND meetings for CGTs.

Who Should Attend


Who should attend this webinar?

Organisation type: Pharmaceutical, Biotechnology, Biopharmaceutical

Job functions:

– Clinical Operations
– Clinical Research
– Commercial
– Executive
– General Management
– Health Economics & Outcomes Research
– Market Access
– Market Research
– Medical Affairs

– Medical Communications
– Medical Operations
– Operations
– Outsourcing
– Portfolio Management
– Procurement
– Product Development
– Project Management
– Regulatory


Click here to register for this free webinar

Event Code of Conduct

This code explains our expectations and rules, which includes general good practice behaviour – because actions can impact others and everyone has a role to play in getting it right.

Anyone not following these rules or behaving in an unacceptable way will be asked – and expected – to stop doing so immediately and may be removed from the event. Read our Event Code of Conduct here.

when & where

25 Oct 2023

FREE Online Webinar

Click here to register

Get all the latest on Informa news and events

Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.

Find out more